Stockreport

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Cybin Inc. Common Shares  (CYBN) 
PDF - Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder (“MDD”) expected imminently -- 12-month efficacy data from Phase 2 study of CYB003 in MDD expec [Read more]